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Blocking Monoclonal Antibodies Specific for Mouse IFN-/
Receptor Subunit 1 (IFNAR-1) from Mice Immunized by
In Vivo Hydrodynamic Transfection
KATHLEEN C.F. SHEEHAN,1 KOON SIEW LAI,1 GAVIN P. DUNN,1 ALLEN T. BRUCE,1
MARK S. DIAMOND,1 JENNIFER D. HEUTEL,1 CORAZON DUNGO-ARTHUR,1 JAVIER A. CARRERO,1
J. MICHAEL WHITE,1 PAUL J. HERTZOG,2 and ROBERT D. SCHREIBER1

ABSTRACT
Herein we report the generation of mouse monoclonal antibodies (mAbs) specific for the IFNAR-1 subunit of
the mouse interferon-/ (IFN-/) receptor (MAR1 mAbs) that block type I IFN receptor signaling and biologic response induction in vitro and in vivo. These mAbs were generated from Ifnar1/ mice immunized
by in vivo hydrodynamic transfection with a plasmid encoding the extracellular domain (ECD) of murine
IFNAR-1. All MAR1 mAbs bound native receptor expressed on cell surfaces and immunoprecipitated
IFNAR-1 from solubilized cells, and two mAbs also detected IFNAR-1 by Western blot analysis. In vitro, the
mAbs prevented ligand-induced intracellular signaling and induction of a variety of type I IFN-induced biologic responses but had no effect on IFN--induced responses. The most effective in vitro blocker, MAR1-5A3,
also blocked type I IFN-induced antiviral, antimicrobial, and antitumor responses in vivo. We also explored
whether murine IFNAR-1 surface expression required the presence of Tyk2. In contrast to Tyk2-deficient human cell lines, comparable IFNAR-1 expression was found on primary cells derived either from wild-type or
Tyk2/ mice. These mAbs represent much needed tools to more clearly elucidate the biochemistry, cell biology, and physiologic function of the type I IFNs and their receptor in mediating host-protective immunity
and immunopathology.

INTRODUCTION

M

OUSE TYPE I INTERFERONS (IFN-/) are a family of cytokines consisting of 14 functional IFN- proteins and
one IFN- protein that play important roles in promoting and
linking innate and adaptive immune responses.1–3 All type I
IFNs bind to the same heterodimeric receptor consisting of two
subunits (IFNAR-1 and IFNAR-2)4,5 that are coexpressed on
nearly all cells. Ligand binding to the IFN-/ receptor complex leads to the tyrosine phosphorylation and activation of
IFNAR-1-associated Tyk2 and IFNAR-2-associated Jak1,
which, in turn, phosphorylate cytosolic Stat1 and Stat2, giving
rise to two types of activated transcription factors: a Stat1 homodimer and IFN-stimulated gene factor 3 (ISGF3), a tripartite
complex of phosphorlyated Stat1, Stat2, and the constitutive
DNA binding protein IFN regulatory factor-9 (IRF-9). The ac-

tivated transcription factors enter the nucleus, bind to specific
enhancer elements (IFN- activation sequence [GAS] and IFNstimulated response element [ISRE] sequences, respectively) on
certain genes, and by regulating the expression of these genes,
induce the wide range of IFN-dependent effects on cellular
function (reviewed in refs. 6–9).
Comparative functional analyses of several members of the
type I IFN family revealed that they induce a significantly overlapping array of biologic responses, although quantitative differences have been noted in the specific activities of each particular form.10,11 A small number of genes have been identified
that are differentially regulated by IFN- vs. IFN-.12,13 Based
on IFN’s wide-ranging activity, a reliable approach to studying
the physiologic functions of the type I IFN family has been to
use gene-targeted mice lacking a functional IFN-/ receptor.
For example, mice lacking the IFNAR-1 receptor subunit are
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completely unresponsive to both endogenously produced and
exogenously administered type I IFNs. Using these mice, it has
been possible to validate the physiologically relevant roles of
the type I IFNs in promoting antiviral, antimicrobial, antitumor,
and autoimmune responses in vivo.14–21
Nevertheless, the use of Ifnar1 gene-targeted mice is often
complicated by the frequent need to breed the receptor deficiency into distinct genetic backgrounds and because of the
high susceptibility that Ifnar1/ mice display to certain viral infections. A proven alternative approach that circumvents
these problems is the use of blocking, receptor-specific monoclonal antibodies (mAb) that can be administered to wildtype mice, rendering them as unresponsive to a particular
cytokine as the corresponding receptor-deficient, gene-targeted mouse.20,22–24 Thus, the availability of IFNAR-1-specific mAbs not only would help in analysis of the biochemistry and cell biology of the IFN-/ receptor but also would
facilitate the elucidation of IFN-/’s physiologic in vivo actions. Although blocking mAbs specific for the human IFN/ receptor subunits have indeed been generated,25–27 similar antibodies specific for the subunits of the murine IFN-/
receptor are not available.
Herein we report the generation of blocking mAbs specific
for murine IFNAR-1 derived from Ifnar1/ mice immunized
by in vivo hydrodynamic transfection using plasmid DNA encoding the extracellular domain (ECD) of murine IFNAR-1. We
also characterize these mAbs using in vitro approaches and document their functional utility in assessing type I IFN’s physiologic functions in vivo, using models of viral and bacterial infection and tumor development. Finally, we use the mAb to
address the unresolved issue of IFN-/ receptor expression in
Tyk2/ mice.

MATERIALS AND METHODS
Mice
Mice lacking the IFNAR-1 subunit of the IFN-/ receptor
(Ifnar1/ mice) were obtained from M. Aguet (ISREC, Laussanne, Switzerland)14 and were maintained on the same 129/SvPas genetic background as the embryonic stem cell from which
they were derived.20 Wild-type 129/SvPas mice were obtained
from Charles River (Wilmington, MA), and 129/SvEv (129 S6)
or C57BL/6 mice were obtained from Taconic Farms (Germantown, NY). Mice were bred and maintained in our specific
pathogen-free animal facility (Washington University School
of Medicine) in accordance with American Association of Laboratory Animal Science guidelines. All animal protocols used
in this study were approved by our Institutional Animal Review
Board.

Cytokines and reagents
Purified recombinant cytokines were obtained from the following sources: MuIFN- from Genentech (South San Francisco, CA), HuIFN-A/D from Hoffmann-LaRoche (Nutley,
NJ), MuIFN-A and MuIFN- from PBL Biomedical Laboratories (Piscataway, NJ), and MuIFN-5 from D. Fremont,
Washington University School of Medicine (St. Louis, MO).
Goat antimouse Ig secondary reagents were obtained from Cal-
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tag Laboratories (Burlingame, CA). GIR-208 is a mouse IgG1
mAb specific for human IFNGR-1 that shows no reactivity with
the mouse proteins22 and was, therefore, used as an isotypematched irrelevant control mAb in this study.

IFNAR-1 Plasmid DNA
A modified Ifnar1 cDNA was prepared that encoded the following sequences in order: (1) the 26-amino acid IFNAR-1 signal sequence (nucleotides [nt] 1–78 of the full-length Ifnar1
coding sequence), (2) a 10-amino acid N-terminal myc peptidetag (EQKLISEEDL),28 (3) the mature 404-amino acid IFNAR1 ECD (nt 79–1287 of the full-length Ifnar1 coding sequence),
and (4) a C-terminal His6 peptide tag. The modified Ifnar1
cDNA was subcloned into the pRK5 mammalian expression
vector using ClaI and XbaI to generate the pRK5.IFNAR1.ecd
plasmid. Coding sequences of all constructs were verified by
DNA sequencing (Big Dye method, Applied Biosystems, Foster City, CA). Plasmid DNA used for immunization was prepared using the Qiagen Endo-Free Mega Kit according to the
manufacturer’s instructions (Valencia, CA).

Generation of mouse mAbs against mouse
IFNAR-1 ECD
Mouse mAbs specific for the ECD of mouse IFNAR-1 were
developed from Ifnar1/ mice immunized by hydrodynamic
injection of plasmid DNA encoding the murine IFNAR-1 ECD.
Briefly, Ifnar1/ mice were injected intravenously (i.v.) over
7 sec with 100 g of the pRK5.MuIFNAR1.ecd plasmid in a
volume of Ringer’s solution corresponding to 10% of the animal’s body weight (i.e., 2.5 mL/25 g mouse).29,30 Following an
additional two rounds of injections on days 10 and 21, strong
IFNAR-1-specific antibody responses were detected in the circulation of most of the injected mice. Seropositive mice with
the highest anti-IFNAR-1 titers were boosted again 30 days
later with 100 g of the same plasmid DNA. To produce the
IFNAR-1-specific mAbs, splenocytes were harvested 4 days after the final boost and were fused to the murine P3X63Ag8.653
myeloma cell line according to published procedures.23 Supernatants from growth-positive wells were screened for the presence of IFNAR-1-specific mAbs by monitoring differential immunostaining of Ifnar1 vs. Ifnar1 murine sarcomas20 as
assessed by flow cytometry. MAR1 mAb were purified by protein A affinity chromatography.22 Bulk quantities of purified
endotoxin-free MARI-5A3 were generated by Leinco Technologies (St. Louis, MO).

Cell lines
Murine methylcholanthrene (MCA)-induced sarcoma cell
lines derived from either IFNAR-1-expressing Rag2/ mice
(RAG2-R1, RAG2-R4), mice lacking the Ifngr1 subunit of the
IFN- receptor (RAD.gR.28), IFNAR-1-deficient Ifnar1/
mice (IFNAR1-R1), or mice lacking both Ifnar1 and Ifngr1
(GAR4, GAR5) were isolated and propagated in R10 medium
as described.20,31,32 GAR4 and GAR5 tumor cells were transduced as described33 with either empty retrovirus or a retrovirus encoding full-length murine Ifnar1 to produce the IFN/-responsive GAR4.AR1.18 and GAR5.AR1 cell lines.20
293 cells (6  106) were also transiently transfected with
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pRK5.MuIFNAR1.ecd (25 g) or empty vector by electroporation (0.25 kV) using a GenePulser and protein-containing supernatant harvested after 2 days. L929 cells were obtained from
ATCC (Rockville, MD). Mouse embryo fibroblasts (MEFs)
were generated according to standard procedures.34 Bone marrow-derived macrophages were generated as previously described.35 CosN cells (7  105) were transfected with 3 g
pRK5-MuIFNAR1.ecd using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) according to standard procedures, and supernatants were harvested after 24–48 h.

Flow cytometry
Samples (100 L) of either hybridoma supernatants or purified mAb (2 g) were incubated with IFNAR-1-deficient GAR4
cells or IFNAR-1-expressing GAR4.AR1.18 cells for 2 h at 4°C.
Cells were washed and incubated for an additional hour at 4°C
with biotin-conjugated goat antimouse IgG (Jackson ImmunoResearch, West Grove, PA). After washing, the cells were resuspended in phosphate-buffered physiologic saline (PBS), incubated 40 min at 4°C with streptavidin-PE (Chromaprobe, St.
Louis, MO), washed, resuspended in PBS containing 10% fetal
bovine serum (FBS), and analyzed on a FACScan (Becton Dickinson, Franklin Lakes, NJ). Immune serum, hybridoma supernatants, and purified MAR1 mAbs were also screened in a similar manner for their ability to detect natural IFNAR-1 on L929
cells, MCA sarcomas, primary splenocytes, and MEFs obtained
from wild-type Ifnar1/ mice or gene-targeted Ifnar1/ mice.
All staining was performed at 4°C.

Immunoprecipitation and Western blot analysis
of IFNAR-1
Splenocytes (1  108) from 129/SvEv mice were lysed in 1
mL of 0.5% NP-40 lysis buffer (50 mM Tris, 150 mM NaCl,
containing protease inhibitors [Sigma, St. Louis, MO], 1:500)
and the lysates were precleared by two treatments with 50 L
of a 1:1 slurry of protein G sepharose (Pharmacia, Piscataway,
NJ). Either 1 L antisera (1:1000 dilution) or 20 g purified antibody was added to the cleared lysates together with 50 L of
the 1:1 protein A/G sepharose slurry, and the mixture was incubated overnight at 4°C. Beads were washed three times with
0.5% NP-40 lysis buffer, followed by one wash with PBS, and
then suspended in 25 L Laemmli buffer (containing 1 L 2ME for reducing conditions) and heated for 8 min at 100°C.
Samples were resolved on 4%–15% Criterion polyacrylamide
gels (Bio-Rad, Hercules, CA), transferred to nitrocellulose, and
analyzed by Western blotting as described elsewhere.22 Specific
proteins were detected by sequential treatments using biotinconjugated antibodies (2 g/mL) and steptavidin-Alexa-680
(1:10,000 dilution) (Molecular Probes, Eugene, OR) and visualized using a LICOR Odyssey imaging system (Lincoln, NE).
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0.1% SDS, and 0.5% DOC, containing a protease inhibitor
cocktail [Sigma, 1:500]) and 2 mM sodium orthovanadate.
Lysate (200 g/lane) was run on 10%–20% Criterion SDSPAGE gels and transferred to nitrocellulose. Membranes were
incubated with Odyssey blocking buffer (LICOR) for 1 h prior
to the addition of polyclonal rabbit antibodies specific for
murine phospho-Stat1 (Cell Signaling, Beverly, MA, 1:1000)
and overnight incubation at 4°C. Nitrocellulose membranes
were washed, incubated with goat antirabbit-IgG-Alexa Fluor680 (Molecular Probes) for 45 min and, after washing, analyzed
on a LICOR Odyssey imaging system. To visualize total Stat1
protein, the membrane was incubated with a mouse Stat1 Nterminal specific antibody (G16920, Transduction Laboratories,
South San Francisco, CA) for 1 h, followed by incubation with
goat antimouse-IgG-Alexa Fluor-800. Staining with mouse antiactin (Sigma, St. Louis, MO) followed by goat antimouseIgG-Alexa Fluor-800 (1:10,000) was used to confirm equivalent loading of cellular protein into each lane. Staining was
visualized as described.

In vitro assays for IFN function
IFN-induced antiviral effects were assessed using a cytopathic effect (CPE) assay that employed L929 cells and vesicular stomatitis virus (VSV Indiana strain, 5  104, TCID50) as
previously described.36 Induction of nitric oxide (NO) was determined using L929 cells stimulated with different types of
IFN and lipopolysaccharide (LPS) as previously described.37,38
Enhancement of MHC class I expression was assessed by flow
cytometry after treatment of the RAG-R4 MCA sarcoma cell
line with different types of IFN for 72 h as described.20

Phamacokinetics
Groups of wild-type or Ifnar1/ mice were injected with either 0.2 mg or 2.0 mg MAR1-5A3 or GIR-208 control mAb intraperitoneally (i.p.) in a volume of 0.5 mL PBS. At each time
point, blood was collected from 2–5 animals (200 L each via
retroorbital sinus). MAR1-5A3 antibody levels in the serum were
determined using an indirect binding inhibition ELISA. Briefly,
plates were coated with purified MAR1-4D12 mAb (200 ng/well),
washed, and then 50 L IFNAR-1.ecd-containing supernatant was
added per well. After 1 h, plates were washed, incubated with dilutions of either serum or unconjugated, purified MAR1-5A3 antibody, and washed again. Biotin-conjugated MAR1-5A3 (0.1 g)
was added to each well, and plates were developed using streptavidin-peroxidase (Zymed, Carlsbad, CA) and ABTS substrate
(Roche, Indianapolis, IN). Values were determined based on a
standard curve of purified MAR1-5A3 diluted in normal mouse
serum. Levels of GIR-208 were directly quantitated by ELISA
using plates coated with murine IFNGR1.ecd protein,39 with values determined based on a standard curve of purified GIR-208 diluted in normal mouse serum.

Phospho-Stat1 immunoblot
L929 cells (5  106) were preincubated with either IFNAR1-specific or irrelevant GIR-208 mAb and stimulated for 15 min
at 37°C with 300 U/mL MuIFN-. Reactions were terminated
by addition of cold medium. The cells were washed and lysed
for 20 min at 4°C by the addition of two volumes of RIPA lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% NP-40,

In vivo assays for IFN function
VSV infection. Groups of 5 wild-type or Ifnar1/ mice were
pretreated with either PBS, 1.25 or 2.5 mg MAR1-5A3, GIR208 mAb, or saline 1 day prior to infection with VSV Indiana
strain (1  106, TCID50, i.v., in 200 L) as described.40 Animals were monitored daily for survival.

IFNAR-1-SPECIFIC mAb
Listeria infection. Groups of 5 wild-type or Ifnar1/ mice
were pretreated with PBS or 2.5 mg of either MAR1-5A3 or
control GIR-208 mAb 1 day prior to infection with Listeria
monocytogenes EGD strain as previously described.18,41 Four
days postinfection, the spleens were harvested, and the numbers of bacteria were counted.
Growth of transplated tumors. Wild-type or Rag2/ mice
(n  3–5) were treated for various times beginning on day 1
with MAR1-5A3 or control GIR-208 mAb (e.g., 500 g on
days 1, 0, 1, and 2 plus; 250 g every other day thereafter) and challenged with 1  106 RAG2-R1 sarcoma cells
subcutaneously (s.c.) on the flank as described.20 Tumor growth
was monitored and recorded as the mean tumor diameter of two
perpendicular measurements.

Generation of Tyk2-deficient mice
Targeting vector. Genomic clones containing portions of the
murine Tyk2 gene were isolated from a Lambda Fix II 129/Sv
genomic library (Stratagene, La Jolla, CA). A 16-kb genomic
Tyk2 clone encompassing the exons for the 5-untranslated region (5-UTR) and the first ATG start codon was used to generate the Tyk2 targeting vector. A 1.2-kb AvaI-SacI fragment
containing the 5-UTR, a 1.5-kb SacI-EcoRI fragment containing the exon coding for the first ATG codon, and a 4.7-kb EcoRI
fragment containing the three exons were cloned, respectively,
into the NotI, AscI, and PmeI sites of the TNLOX1-3 targeting
vector.42
Transfection of ES cells and generation of Tyk2-deficient
mice. The Tyk2 targeting vector (20 g) was linearized by SalI
digestion and electroporated into the MC-50 embryonic stem
cell line generated in our laboratory. Following double selection, single colonies were analyzed for homologous recombination by PCR using the following set of primers: 5Sac412F
primer
ATGCATCATACACACACATGTGAG
and
Neo1547F primer GAAGACAATAGCAGGCATGCT. The
frequency of homologous recombination events was 1:236. The
complete integration of the 3 region, including the downstream
loxP3 site, was verified by PCR using 3P1F primer GATCCTCACAAGTTCCAGTC and 3P4R primer CTGGGAGAGCAGCCACTGCTC. The targeted ES cell clone, M83,
was then transiently transfected with an expression vector pMCcre, which encodes the Cre-recombinase.42 Colonies were
screened by PCR using M180F primer CGGATGCACATAGCACTGTGTAGC and 3P4R primer as described. The ES cell
clone, GK-76, in which the PGK-neo cassette plus the 1.5-kb
gene segment were deleted, was used to microinject into blastocysts to generate Tyk2-deficient mice.
Genotyping by Southern blot, PCR, and Western blot. Southern blot analysis was performed on 25 g BamHI-digested genomic DNA as described.40 The filter was probed with a 32Plabeled external probe (3EP). To genotype mice by PCR
genomic DNA samples were amplified with M180F and 3P4R
primers. The samples were amplified in the following manner:
1 cycle at 940C for 5 min; 35 cycles at the following conditions: 94°C for 30 sec, 65°C for 30 sec, and 72°C for 90 sec;
and finally 1 cycle at 72°C for 5 min. A PCR product of 240bp fragment derived from the targeted allele and a 1.5-kb fragment derived from the wild-type allele were resolved on a 1.5%
TBE agarose gel. Western blot analysis was performed on
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lysates of bone marrow macrophages as described40 using
Tyk2 antisera obtained from Santa Cruz Biotechnology (Santa
Cruz, CA).

RESULTS
In vivo genetic hydrodynamic immunization
In vivo hydrodynamic transfection of naive wild-type mice or
Ifnar1/ mice with a plasmid encoding the ECD of murine
IFNAR-1 engineered to express an N-terminal myc tag and a
C-terminal His6 tag resulted in the accumulation of soluble
tagged forms of IFNAR-1.ecd protein in the blood in both types
of mice. As evidenced by immunoprecipitation with anti-myc
and Western blot analysis with labeled anti-myc, the tagged
IFNAR1.ecd was detected as early as 10 h postinjection and persisted for 1 week in both types of mice (data not shown). However, when the mice were subjected to a second round of in vivo
hydrodynamic transfection, soluble IFNAR-1 was detected only
in the blood of wild-type mice but not Ifnar1/ mice. The sera
obtained from the latter but not the former contained IFNAR1-specific antibodies as evidenced by flow cytometry using
Ifnar1/ MCA-induced murine sarcomas generated in Rag2/
mice (RAG2-R4) (Fig. 1A and 1B, respectively). Serum titers
in some of these twice-transfected Ifnar1/ animals exceeded
1:10,000, as detected by FACS analysis (data not shown). Thus,
the subsequent absence of detectable IFNAR-1.ecd in the circulation of hydrodynamically transfected Ifnar1/ mice was
explained by the development of an antibody response against
the foreign soluble IFNAR-1 protein.
To further assess the specificity of the antibody response generated in hydrodynamically transfected Ifnar1/ mice, sera
from these mice were tested by flow cytometry using a variety
of IFNAR-1-expressing and IFNAR-1-deficient cell lines.
Whereas sera from transfected Ifnar1/ mice failed to stain
the Ifnar1-deficient GAR4 MCA sarcoma line derived from a
mouse lacking both IFNAR-1 and IFNGR120 (Fig. 1D), homogeneous positive staining was observed on GAR4 cells that
had been stably transduced with a retrovirus encoding fulllength, wild-type IFNAR-1 (GAR4.AR1.18 cells)20 (Fig. 1C).
The same sera also stained an MCA sarcoma from a mouse that
naturally expressed wild-type IFNAR-1 (RAG2-R1) (Fig. 1E)
but not a sarcoma derived from a gene-targeted mouse that
lacked the protein IFNAR1-R2 (Fig 1F).20 Furthermore, the
serum detected IFNAR-1 on type I IFN-responsive murine L929
fibroblasts, and staining was blocked if the cells were preincubated at 4°C with a combination of 10,000 U each of MuIFNA and MuIFN- (Fig. 1G,H). Thus, in vivo hydrodynamic
transfection of Ifnar1/ mice with plasmid DNA encoding the
ECD of IFNAR-1 led to induction of antibodies reactive to the
native receptor expressed on cell surfaces.

Generation of IFNAR-1-specific mAbs
Following multiple rounds of in vivo hydrodynamic transfection of Ifnar1/ mice with the IFNAR-1.ecd plasmid, the
spleen of 1 immunized mouse was harvested, and splenocytes
were fused to murine myeloma cells to generate mAb.22 As assessed by differential staining of GAR4 and GAR4.AR1.18
cells, one third of the growth-positive wells (138 of 415) con-
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tained antibody that specifically reacted with the ectopically expressed receptor. Culture supernatants from 23 of 65 strongly
positive cell lines also reacted with IFNAR-1-expressing
RAG2-R1 cells. All but 2 of these antibodies were of the IgG1
isotype. Five separate hybridomas (MAR1-1H5, MAR1-3A7,
MAR1-4D12, MAR1-4F12 and MAR1-5A3) were selected,
subcloned by limiting dilution, and expanded, and the specific
IgG1 that was purified from spent culture supernatants was used
in the subsequent analyses.

SHEEHAN ET AL.

MAR1 mAbs recognize native IFNAR-1
The specificity of each purified MAR1 mAb was assessed
using two different approaches. First, when analyzed by flow
cytometry, each mAb stained IFNAR-1-expressing RAG2-R1
sarcoma cells (Fig. 2A, top) but did not stain IFNAR1-R2 sarcoma cells derived from an Ifnar1/ mouse (Fig. 2A, bottom).
Second, each MAR1 mAb was examined for the ability to immunoprecipitate natural IFNAR-1-derived from cell lysates of
129/Sv mouse splenocytes. When these immunoprecipitates
were subjected to SDS-PAGE and analyzed by Western blotting using biotin-conjugated MAR1-5A3 (Fig. 2B), each MAR1
mAb precipitated a single 100-kDa component that displayed
an Mr consistent with that reported for natural murine IFNAR1. This band was not present in precipitates generated with the
GIR-208 control mAb. In contrast, when used as detection
reagents in Western blot analyses, only MAR1-5A3 and MAR11H5 reacted with IFNAR-1 separated by SDS-PAGE under either reducing (data shown) or nonreducing (data not shown)
conditions (Fig. 2C).

MAR1 antibodies block type I IFN-induced
Stat1 phosphorylation
To assess the effects of the MAR1 antibodies on IFN-/induced cellular responses, we first asked whether the mAbs
could block IFN-/-dependent phosphorylation/activation of
the transcription factor Stat1. Pretreatment of murine L929 cells
with each of the MAR1 mAbs led to a 60%–88% inhibition of
MuIFN-5-dependent Stat1 phosphorylation (Fig. 3). Inhibition was not observed in cells treated with control GIR-208
mAb. Similar results were obtained in other experiments in
which IFN-/ receptor signaling was assessed by monitoring
nuclear translocation of activated Stat1 as detected using confocal microscopy.43 Here again, pretreatment of either L929
cells or RAG-R2 sarcomas with individual MAR1 mAb inhibited Stat1 nuclear accumulation following stimulation for 15–30
min with different forms of type I IFNs (100 U/mL HuIFNA/D, MuIFN-A, or MuIFN-). Thus, all five MAR1 mAbs
blocked IFN--induced receptor signaling, and four of five (all
except MAR1-4D12) prevented IFN--induced Stat1 activation
(data not shown).

FIG. 1. Detection and specificity of plasmid-induced humoral
response. Indicated cell lines were stained using preimmune or
immune sera at a 1:1000 dilution, followed by PE-conjugated
goat antimouse Ig. Fluorescence intensity was analyzed by flow
cytometry. Gray line indicates secondary antibody alone, solid
line signifies control normal mouse sera, and bold line symbolizes immune sera. (A and B) RAG2-R4 sarcoma stained with
sera obtained from Ifnar1/ or wild-type mice, respectively,
following hydrodynamic genetic immunization. Serum obtained preimmunization or postimmunization of Ifnar1/ mice
using plasmid encoded IFNAR-1.ecd was used in C, D, E, F,
G, and H. (C and D) The murine fibrosarcoma GAR4 (derived
from an MCA-treated Ifngr1/  Ifnar1/ mouse) and
GAR4.AR1.18 (transfected with full-length murine Ifnar1). (E
and F) MCA-induced sarcoma lines obtained from either wildtype 129/SvEv (RAG2-R2) or Ifnar1/ mice (IFNAR1-R2).
(G and H) L929 cells preincubated in buffer or cytokines
(10,000 U each of IFN- and IFN-).
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FIG. 2. Detection of native IFNAR-1. (A) The IFNAR-1-expressing wild-type tumor RAG2-R1 and the Ifnar1-deficient tumor
cell line IFNAR1-R2 (106 cells/well) were stained with 2 g of each purified MAR1 mAb (thick line) or control Ig (thin line)
and detected with secondary antibody, PE-conjugated goat antimouse Ig. (B) Immunoprecipitation of 129/SvEv splenic lysates
(1  108 cells/lane) using 5 g of individual MAR1 mAb or control Ig plus protein G sepahrose. Protein was visualized with biotin-conjugated MAR1-5A3. (C) Western blot analysis of 129/SvEv splenic lysates immunoprecipitated with either MAR1 mAb
or control Ig and detected with individual biotin-conjugated MAR1 mAb or control Ig. Native IFNAR-1 appears as a 100-kDa
band.

MAR1 antibodies block classic type I IFN-induced
cellular responses in vitro
Because the signature functional activity of the type I IFNs
is to protect cells against viral infection, we tested the capacity of the MAR1 mAbs to block IFN-induced antiviral activity
using a CPE assay that employed L929 cells and VSV. Each
of the five MAR1 mAbs displayed a dose-dependent ability to
block antiviral activity induced by 10 U of either HuIFN-A/D
(Fig. 4A) or MuIFN-A (Fig. 4B). Whereas four of the MAR1
mAbs also blocked IFN--induced antiviral activity, MAR14D12 did not (Fig. 4C). MAR1-5A3 consistently displayed the
most potent blocking activity of any of the receptor-specific
mAbs tested regardless of the specific type I IFN used. None
of the mAbs inhibited IFN--induced antiviral activity in the
same assay system (Fig. 4D; data not shown).
Stimulation of a variety of cells with type I IFNs plus LPS
causes the expression of the inducible form of nitric oxide synthase (iNOS), leading to production of NO, which has potent

antimicrobial effects.44–46 Therefore, we also tested the capacity of the MAR1 mAbs to block iNOS induction in L929 cells
treated with a combination of LPS and either HuIFN-A/D,
MuIFN-A, or MuIFN-. Again, all the mAbs specifically inhibited HuIFN-A/D (Fig. 4E) and MuIFN-A (Fig. 4F) induced
iNOS induction (as evidenced by monitoring accumulation of
the stable NO product, nitrite, in the medium) in a dose-dependent fashion. Four mAbs also inhibited IFN--induced
iNOS expression (Fig. 4G). As was the case for antiviral activity, MAR1-5A3 displayed the most potent and most generalized inhibitory capacity of all the mAbs, and MAR1-4D12 inhibited iNOS induction by MuIFN- and HuIFN- but not by
MuIFN- (Fig. 4E, F, G). None of the mAbs inhibited NO induction by MuIFN- (Fig. 4H; data not shown).
Type I or type II IFNs also upregulate expression of many
of the components that participate in the MHC class I antigen
processing and presentation pathway. For example, H-2Kb expression on the surface of RAG2-R4 sarcoma cells increases
significantly (50–90 channel shift) when cells are cultured for
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FIG. 3. Inhibition of Stat1 phosphorylation. L929 cells (5  106) were first treated with MAR1 or control Ig (10 g/mL) and
then stimulated with 300 U/mL MuIFN- for 15 min. Cellular lysates were separated on SDS-PAGE and transferred to nitrocellulose. Blots were stained for (A) phospho-Stat1, (B) total Stat1 protein, and (C) actin, and binding was visualized using a
LICOR Odyssey imaging system. (D) Values represent the relative staining intensity for phospho-Stat1 normalized to total Stat1
staining.

72 h with 300 U/mL of either HuIFN-A/D, MuIFN-A, or
MuIFN- (Fig. 4 I, J, K). In contrast, MHC class I upregulation was attenuated in a dose-dependent manner when the
cells were pretreated with each of the MAR1 mAbs. Although
MAR1-5A3 completely suppressed IFN-/-dependent enhancement of H-2Kb expression, its specific activity was not
significantly greater than that of any of the other MAR1 mAbs.
MAR1-5A3 did not inhibit IFN--induced MHC I expression
(Fig. 4L). Similar results were obtained when either L929
murine fibroblasts or a variety of MCA-induced sarcoma lines
were used as indicator cells (data not shown).

MAR1-5A3 pharmacokinetics
Before assessing the in vivo efficacy of the IFNAR-1-specific mAbs, we first determined their pharmacokinetics. When
naive 129/Sv mice were injected i.p. with a single 0.2-mg dose
of MAR1-5A3, we were surprised to find that the mAb displayed a circulatory half-life (t1/2) of only 1.8 days compared
with 10 days for the irrelevant, isotype-matched GIR-208 control mAb (Fig. 5A). This unusually rapid clearance rate was not
immune mediated, as no anti-MAR1-5A3 reactivity could be
detected by ELISA in the sera of either naive mice or mice that
received multiple injections of the antibody (data not shown).
Moreover, the t1/2 of 0.2 mg of MAR1-5A3 was the same in
both naive animals and mice that had been treated weeks before with similar doses of MAR1-5A3 (Fig. 5A). We subsequently found that two other IFNAR-1-specific mAbs (MAR1-

1H5 and MAR1-4D12) displayed similar rapid clearance kinetics (data not shown). Therefore, we considered the possibility that the rapid disappearance of the MAR1 antibodies from
the circulation reflected their absorption by an unanticipated
large cellular pool of IFNAR-1 expressed on cells in vivo. To
test this hypothesis, we repeated the mAb clearance study in Ifnar1/ mice and found that the serum half-life of low-dose
MAR1-5A3 increased to 7.5 days and was now similar to that
of control IgG (Fig. 5B). Based on this finding, we repeated the
pharmacokinetics analysis in wild-type mice but injected 2 mg
of MAR1-5A3. Under these conditions, MAR1-5A3 displayes
a t1/2 of 5.2 days, which was comparable to that of the control
GIR-208 mAb (t1/2  7 days) (Fig. 5C). Taken together, these
data suggest that a large pool of IFNAR-1 may be present in
normal mice that would require a substantial bolus of mAb to
saturate this receptor pool. No significant differences were observed in leukocyte populations derived from spleen and blood
obtained from mice treated with one or more injections of the
MAR1-5A3 mAb, indicating that this mAb did not cause cell
depletion (Table 1). Because MAR1-5A3 was the IFNAR-1
mAb that displayed the most potent in vitro receptor blocking
activity, all subsequent in vivo experiments were conducted using purified, pyrogen-free, and aggregate-free MAR1-5A3.

Enhanced mortality to VSV in MAR1-5A3-treated mice
Mice unable to respond to IFN-/ (e.g., Ifnar1/ mice
and Stat1/ mice) are more susceptible to viral infection
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FIG. 4. MAR1 mAbs neutralize type I IFN activity in vitro. (A, B, C, and D) Blockade of type I IFN induced antiviral activity. L929 cells (3  104/well) were preincubated with titrations of MAR1 (MAR1-5A3, black squares; MAR1-4F12, inverted
black triangles; MAR1-4D12, gray triangles; MAR1-3A7, black circles; or MAR1-1H5, black diamonds) or control Ig (open
squares) for 1 h at 37°C, and the cultures were stimulated with type I IFN (10 U/well) overnight. Monolayers were washed to
remove free antibody and cytokine, infected with VSV Indiana, and cultured an additional 48 h. Cell viability was assessed visually and by vital dye staining with crystal violet. (D) L929 cells were preincubated with buffer, MAR1-5A3, or control Ig (10
g/mL) prior to stimulation with MuIFN- (10 U/well). (E, F, G, and H) Blockade of IFN--induced NOS. L929 cells (6 
104/well) were preincubated 1 h at 37°C with titrations of MAR1 mAbs (as described) and exposed to HuIFN-A/D, MuIFN-,
or MuIFN- (100 U/well) plus LPS (5 ng/well). After 48 h of culture, supernatants were harvested and assayed for production
of nitrites. (H) L929 cells were preincubated with buffer, MAR1-5A3, or control Ig (10 g/mL) prior to stimulation with MuIFN (100 U/mL) plus LPS. (I, J, K, and L) Inhibition of type I IFN-induced MHC I. RAG2-R4 sarcoma cells were pretreated for
1 h with the indicated concentrations of MAR1 mAb or control Ig and stimulated with type I IFN (1000 U/mL) for an additional
72 h of culture. Cells were harvested and stained for H2-Kb or irrelevant H2-Kk and analyzed by flow cytometry. Data are representative of four similar experiments using L929, murine sarcoma lines, or MEFs. (L) RAG2-R4 cell culture with buffer, MAR15A3, or control Ig (10 g/mL) prior to stimulation with MuIFN- (300 U/mL).

than are wild-type mice. As shown in Figure 6, Ifnar1/
mice succumbed rapidly to infection with VSV, whereas
wild-type mice pretreated with either PBS or 2.5 mg control
GIR-208 mAb displayed no morbidity. In contrast, wild-type
129/Sv mice treated with a single injection of two different
doses of MAR1-5A3 showed enhanced susceptibility to VSV
infection similar to that observed in the Ifnar1/ mice.40,47
Whereas all the Ifnar1/ mice died within 4 days of infection, the time to death of wild-type mice treated with 2.5 mg
MAR1-5A3 was approximately 10 days. Wild-type mice
treated with 1.25 mg of IFNAR-1 mAb died at the same rate
as mice receiving the higher mAb dose, but only 80% of this
group succumbed to infection. MAR1-5A3 is thus able to
block the protective effects of endogenously produced type I
IFN during viral infection in vivo as well as in vitro. Similar

effects were seen following administration of MAR1-1H5
(data not shown).

Control of Listeria infection
Type I IFNs have been shown to control the in vivo response
to L. monocytogenes in mice but, surprisingly, inhibit development of host-protective anti-Listeria responses. Specifically,
Ifnar1/ mice are more resistant to Listeria infection, clear the
bacteria more efficiently, and show considerably less lymphocyte apoptosis in their spleens than their wild-type counterparts.17,18,48 We, therefore, examined the effect of MAR1-5A3
treatment on the course of Listeria infection in normal mice.
Wild-type 129/Sv mice treated with either PBS or control GIR208 mAb were highly susceptible to Listeria infection, as in-
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dicated by the presence of high numbers of the organisms in
the spleens of infected mice. In contrast, Ifnar1/ mice were
resistant to infection and displayed 2 logs fewer bacteria in the
spleen. Wild-type mice pretreated with a single 2.5-mg dose of
MAR1-5A3 were also more efficient in controlling Listeria infection than control wild-type mice, and the spleens of the
MAR1-5A3-treated mice contained significantly less Listeria
than did controls (Fig. 7). Thus, these results demonstrate that
antibody blockade of the IFN-/ receptor mimics the genetic
receptor deficiency in this model of bacterial infection challenge.
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We previously showed that endogenously produced type I
IFNs are critical to the development of the host antitumor responses against primary, carcinogen-induced, and transplantable tumors.20 Continuous treatment of wild-type mice
with MAR1-5A3 inhibited rejection of several immunogenic
MCA sarcomas that were efficiently eliminated in either untreated, naive, syngeneic wild-type hosts, or wild-type mice
treated with GIR-208 mAb. To establish the temporal requirements for IFN-/ during successful antitumor immune responses, we asked whether antibody blockade needed to be
maintained throughout the entire rejection process. Groups of
wild-type 129/Sv mice were, therefore, treated for varying time
periods with MAR1-5A3 or control GIR-208 mAb and challenged with highly immunogenic RAG2-R1 sarcoma cells. As
reported previously, RAG2-R1 sarcomas grew progressively
when transplanted into immunodeficient Rag2/ mice (Fig. 8
A, B, C), but were rejected when transplanted into wild-type
mice treated with control GIR-208 mAb (Fig. 8 D, E, F). Also,
consistent with our earlier report, RAG2-R1 tumors grew progressively in 4 of 5 wild-type mice treated continuously with
MAR1-5A3 (i.e., treatment on days 1, 0, 1, 2, and every
other day until day 21) (Fig. 8G). Interestingly, RAG2-R1 tumors also grew progressively in wild-type mice treated with
MAR1-5A3 even when mAb treatment was discontinued after
day 2 (treated days 1, 0, 1, and 2) (Fig. 8H). More importantly, progressive tumor growth was still observed in the
majority of mice (3 of 5) treated with MAR1-5A3 only during
the time frame of days 6 to 9 (Fig. 8I). These data indicate
that type I IFNs act not only early, at the initiation of the immune response to an immunogenic tumor, but also late during
the effector phase of tumor rejection.
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FIG. 5. Complexity of MAR1-5A3 pharmacokinetics. (A)
129/SvEv mice were injected with a single 0.2 mg i.p. dose of
MAR1-5A3 (black squares) or control GIR-208 mAb (open
squares). Serum was sampled at various time points and analyzed for Ig concentration. Additional groups of 129/SvEv mice
were given repeated injections of 0.2 mg MAR1-5A3 (gray circles) at 8 week intervals and similarly monitored for circulating antibody. (B) Wild-type (black squares) or Ifnar1/ (open
triangles) mice were also injected with 0.2 mg MAR1-5A3.
Wild-type mice were similarly treated with 0.2 mg GIR-208 as
in A (open squares). (C) A saturating dose (2 mg) of MAR15A3 (black squares) or control Ig (inverted gray triangles), was
injected into 129/SvEv mice and analyzed as in A.
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TABLE 1.

MAR1-5A3 IS NONDEPLETING IN VIVO CELLa
MAR1-5A3
treatment
(2.5 mg)

Saline
treatment

Marker
CD3
CD4
CD8
B220
F4/80

16.7
10.7
5.7
33.4
4.6







106
106
106
106
106

(32.2)b
(20.6)
(10.9)
(64.2)
(8.8)

14.3
9.3
4.9
27.8
4.5







106
106
106
106
106

Control Ig
treatment
(2.5 mg)

(32.5)
(21.2)
(11.1)
(63.1)
(10.2)

12.4
8.2
4.2
30.3
4.9







106
106
106
106
106

(28.1)
(18.7)
(9.5)
(68.9)
(11.1)

aMice (129/Sv) were treated with saline, MAR1-5A3 (2.5 mg), or control Ig (2.5 mg) i.p., and 4 days later, splenocytes were
harvested and analyzed for surface marker expression by flow cytometry. Numbers represent cells expressing the indicated
marker.
b% of total cells.

Detection of IFNAR-1 on Tyk2-deficient cells
Having demonstrated the specificity and blocking activity of
the MAR1 mAbs, we used them to address the unanswered
question of whether murine IFNAR-1 expression at the cell surface required an interaction with Tyk2. Previous studies using
human cell lines have shown that membrane expression of human IFNAR-1 is stabilized by the association of Tyk2 with the
intracellular domain of IFNAR-1.49–51 These studies further
showed that a human cell line lacking Tyk2 was unresponsive
to HuIFN-. These data suggest that in human cells, Tyk2 may
be a key factor regulating IFNAR-1 surface expression, recycling, and function. In contrast, genetic disruption of the Tyk2
gene in mice leads to only partial cellular insensitivity to many
of the cytokines that engage Tyk2-associated receptor subunits
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(e.g., IFN-/, interleukin-10 [IL-10], and IL-12). Because of
the absence of antibodies that could detect murine IFNAR-1 on
cell surfaces, it has not been possible to assess whether Tyk2
plays as important a role in IFNAR-1 expression in mice as it
does in humans. We, therefore, used the MAR1-5A3 mAb to
examine murine IFNAR-1 expression levels on MEFs or splenocytes obtained from wild-type, Tyk2-deficient or Ifnar1/
animals. Staining with biotin-conjugated MAR1-5A3 revealed
similar levels of IFNAR-1 expression on MEF lines derived
from genetically matched wild-type or Tyk2-deficient animals
(Fig. 9A, B). Tyk2 deficiency was confirmed by Southern blot
analysis (data not shown) and Western blot analysis (Fig. 9D).
No MAR1-5A3 staining was detected on primary MEFs obtained from Ifnar1/ mice (Fig. 9C). In addition, no statistically significant differences in surface IFNAR-1 levels between
wild-type and Tyk2/ splenocyte subpopulations (CD3,
CD4, CD8, B220, F4/80, or DC3/DX5) were detected
(paired t-test, p  0.53–0.182) (Fig. 9E). Identical results were
also obtained using the MAR1-4D12 mAb, which binds an epitope distinct from that recognized by MAR1-5A3 (data not
shown). Thus, these novel MAR1 reagents provide the first opportunity to study murine IFNAR-1 expression on cell surfaces
and should facilitate the analysis of cytokine receptor trafficking, particularly with respect to the effects of Tyk2 on receptor localization.
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FIG. 6. Protection from viral infection/neutralization of endogenous type I IFN. IFN-R/ (open squares) or wild-type
129/Sv mice (n  5–6 per group) were left untreated (open circles), pretreated with either saline (black circles), control IgG1
(black squares), MAR1-5A3 (2.5 mg/mouse) (inverted black
triangles), or 1.25 mg/mouse (open triangles) i.p. on day 1.
Mice were infected with VSV (Indiana strain) 4.5  104
TCID50 i.v. and observed daily. Data are representative of three
experiments.

This paper describes a strategy to generate murine mAbs specific for soluble murine proteins, using a combination of in vivo
genetic immunization and in vitro somatic cell fusion techniques. It also presents a novel use for these mAbs to neutralize IFN-/ at different times during an ongoing in vivo response, an advantage that the use of gene-targeted mice does
not allow. In this study, we took advantage of the availability
of gene-targeted Ifnar1-deficient mice capable of mounting a
humoral response against the soluble IFNAR-1 ectodomain
whose expression in adult mice was transiently induced by genetic hydrodynamic transfection. Genetic immunization provided an efficient alternative to work-intensive, conventional
procedures for producing and purifying soluble antigens. The
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FIG. 7. Control of Listeria infection. 129/SvEv or Ifnar1/
mice were pretreated with PBS, control Ig, or MAR1-5A3 (2.5
mg/mouse) 1 day prior to infection with Listeria. Four days
later, spleens were harvested and homogenized, and the number of bacterial colonies was enumerated. Colony counts for
MAR1-5A3-treated animals were significantly different from
those obtained from animals treated with control Ig (Mann
Whitney test, p  0.0343). Data represent two combined experiments.
use of gene-targeted mice provided a host that recognized the
reintroduced murine protein as a foreign antigen.
The in vivo hydrodynamic transfection procedure used in this
study was developed by others29,30 and is based on hepatocyte
uptake of cDNAs injected i.v. under high pressure, which in
turn leads to high-level production of the encoded protein by
the cells. In the current study, we employed a cDNA that encoded a secreted form of the mouse IFNAR-1 protein that constituted the entire ECD of the receptor subunit. At present, we
do not know if this same procedure can be used to generate antibodies against intracellular proteins, such as kinases and transcription factors, and it may require reengineering an intracellular protein for secretion by addition of a hydrophobic signal
sequence at the N-terminus. Moreover, the hydrodynamic transfection/splenocyte fusion technique used herein has only been
optimized thus far for matched pairs of gene-targeted mice and
the corresponding proteins they lack. Nevertheless, we assume
this approach will be applicable to situations involving wildtype mice and cDNAs encoding proteins of other species. A recent report by Bates et al.52 compares two methods of i.v. delivery of plasmid DNA for the development of antigen-specific
polyvalent antisera in mice rats and rabbits. They, too, found
that this method of plasmid-based immunization is effective in
generating humoral responses to a range of protein antigens in
mice and that these mice are a suitable source of immune B
cells for hybridoma generation and the isolation of mAb.52
The immune sera from hydrodynamically transfected, genetargeted mice were particularly well suited for use in immunostaining/flow cytometry and also immunoprecipitation/Western blot analyses (data not shown) and did not require
preabsorption, as is often needed with conventionally produced
antiprotein sera generated using adjuvants. Moreover, the fact
that most of the hybridomas produced blocking IgG1 mAbs
showed that in vivo hydrodynamic transfection/immunization
not only induced class switching but also caused affinity maturation of B cells that recognized functionally relevant anti-

genic determinants on the IFNAR-1 protein such that the mAbs
they produced inhibited the effects of IFN ligands that bind to
the IFN-/ receptor with pM affinities. Finally the protocol
produced at least one mAb (MAR1-5A3) that blocked type I
IFN effects in vivo without depleting IFNAR-1-bearing cells,
demonstrating that the procedure was useful in developing mAb
suitable to probe the physiologic functions of this cell surface
receptor. Thus, the protocol outlined in this study yielded
heretofore unavailable mAbs suitable for analyzing IFNAR-1
on a biochemical, cell biologic, and functional basis both in
vitro and in vivo.
Each of the five MAR1 mAbs characterized in this report
bound IFNAR-1 either when it was expressed on the surface of
intact cells or when it was released from solubilized cell membranes. When analyzed for antigen-binding specificity the
mAbs were found to cluster into two distinct groups. The mAbs
MAR1-5A3, MAR1-1H5, MAR1-3A7, and MAR1-4F12 comprised one group and cross-competed with one another for binding to wild-type IFNAR-1, as assessed by flow cytometry and
ELISA, but did not compete for IFNAR-1 binding with the second group comprising only MAR1-4D12. In fact, MAR1-4D12
and MAR1-5A3 can function as capture and detection reagents,
respectively, in an ELISA that is specific for soluble IFNAR1. Interestingly, the two specificity groups displayed distinct
capacities to block cellular responses induced either by IFN-
or IFN-. Whereas each of the four antibodies in the first group
inhibited a variety of cellular responses induced by either IFN or IFN-, MAR1-4D12 inhibited only IFN--induced responses. This result suggests that IFN- and IFN- may differ
in the manner in which they interact with the IFN-/ receptor complex, a result consistent with the currently held concept
of human type I IFN binding to its receptor.53,54
Although more work is needed to better define the epitope
specificities seen by each of the MAR1 antibodies, our findings
are consistent with the work of others who have proposed distinctive receptor binding specificities of IFN- vs. IFN-.53–57
Previous structure-function analyses using human cell lines revealed that although IFNAR-2 appeared to be the primary ligand-binding chain,5 coexpression of IFNAR-1 and IFNAR-2
was required for high-affinity ligand binding and cellular activation (reviewed in ref. 9). Several groups have also presented
evidence characterizing the binding of specific human IFN-
subtypes with distinct human IFNAR-1 domains and have
linked the strength of ligand binding with the range of biologic
activities induced.12,47,58 In addition, studies with Ifnar1 genetargeted mice show a lack of functional activity despite the detection of limited ligand binding. Clearly, more definitive analyses will be required to understand the mechanism by which
specific ligands interact with IFNAR-1 and IFNAR-2 to trigger biologic responses.
As we prepared to use the mAbs in in vivo experiments, we
were struck by the highly unusual pharmacokinetics that they
displayed in wild-type mice. Specifically, when injected into
normal mice at relatively low doses (200 g/mouse), the antibodies rapidly disappeared from the circulation, displaying a
serum half-life of 1.8 days, which was more than 5 times faster
than that of isotype-matched control IgG (t1/2  10 days). The
accelerated clearance of the MAR1 mAbs is, thus, distinct from
that of mAbs specific for other cytokine receptors (e.g., IFNGR1, tumor necrosis factor receptor 1 [TNFR1], or TNFR2).22,23
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FIG. 8. Blockade of tumor rejection. 129/SvEv mice were treated with MAR1-5A3 (G, H, and I) or control Ig (D, E, and F)
for various periods of time as indicated and inoculated with RAG2-R1 tumor cells (1  106 /mouse). Tumor growth was monitored over 30 days. Rag2/ mice (A, B, and C) were similarly inoculated with tumor lines as a control for cell growth in vivo.
Each line represents the tumor growth kinetics in individual mice. Data are representative of two experiments.

This anomalous behavior could not be explained by the presence of soluble forms of IFNAR-1, as immunoprecipitation/Western blot analysis of sera from unmanipulated mice did
not reveal detectable levels of soluble IFNAR-1. This is consistent with the prediction for the gene structure of IFNAR-1,
which indicates no alternative splicing. Importantly, this result
is distinct from studies with IFNAR-2, which produces a soluble isoform by alternative splicing and which has been detected
in serum.59 Nor could it be explained by the presence of preexisting or induced antibodies against the IFNAR-1 mAbs as
assessed by ELISA.
Two important clues helped resolve this dilemma. The first
came from the observation that the serum half-life of the receptor mAbs normalized when the pharmacokinetics were performed in Ifnar1/ null mice (t1/2  7.5 days). The second
came from the finding that the half-life of MAR1-5A3 stabilized when we injected 10 times more antibody. These results

are consistent with the conclusion that wild-type mice possess
a large depot of IFNAR-1 that needs to be saturated before excess antibody can appear in the circulation. Yet, as determined
in preliminary Scatchard analyses, primary murine lymphocytes, macrophages, and fibroblasts express only approximately
1000 surface receptors per cell (unpublished observations). In
addition, as assessed by flow cytometry, we have not yet found
a primary cell population that expresses extremely high levels
of cell surface IFNAR-1. Unfortunately, the MAR1 mAbs do
not function in immunohistology using either frozen or fixed
tissue sections, although we are currently pursuing imaging
studies to compare IFNAR-1 tissue expression. Thus, we currently favor the hypothesis that a large pool of IFNAR-1 may
be present within certain cells, and as intracellular IFNAR-1
cycles to the cell surface, it absorbs IFNAR-1 mAb out of the
circulation. This hypothesis is consistent with the finding that
in human cell lines, IFNAR-1 can cycle rapidly between the
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FIG. 9. IFNAR-1 expression on Tyk2-deficient cells. MEF derived from 129/SvEv (A) wild-type, (B) Tyk2-deficient, or (C)
Ifnar1/ mice were analyzed for expression of IFNAR-1 using biotin-conjugated MAR1-5A3 or control Ig, followed by streptavidin-PE. Gray lines represent unstained cells, thin lines represent control Ig staining, and bold lines indicate MAR1-5A3stained cells. (D) Tyk2 deficiency is confirmed in gene-targeted mice used to generate primary MEF lines by Western blot analysis. (E) Splenocytes from wild-type 129/SvEv, Tyk2/, or Ifnar1/ mice were analyzed for dual expression of FITC-conjugated
or PE-conjugated cell surface markers and biotin-conjugated MAR1-5A3, followed by streptavidin-APC. The ratio of the geometric mean fluorescent intensities of MAR1-5A3/control Ig staining are shown. Data represent the average of three separate experiments expressed as the mean SD.

plasma membrane and intracellular stores.49 More work is
needed to quantitate the absolute amounts and relative distribution of IFNAR-1 within cells vs. on the cell surface and to
explore whether the subcellular compartmentalization of
IFNAR-1 differs between distinct cell populations.
The demonstration that MAR1-5A3 effectively inhibited all
type I IFN responses in vitro and could be injected multiple
times in vivo and not provoke an antibody response suggested
that it might be useful to block type I IFN responses in vivo.
Clearly, the availability of gene-targeted mice lacking Ifnar1
has significantly enhanced our understanding of the role of IFN/ in host defense and autoimmunity. However, the use of
gene-targeted mice is often complicated by genetic issues of
mouse background (e.g., we have recently found that the

Ifnar1/ mouse is actually on a 129/SvPAS genetic background, and not on a 129/SvEv background as reported by the
distributor20) and often experimental in vivo models require that
the mice be on particular genetic backgrounds. Thus, the ability to render a wild-type mouse insensitive to type I IFNs using a blocking IFN-/ receptor mAb has distinct advantages,
including the ability to examine the effect of type I IFN blockade at different stages of immune induction or disease progression.
To validate the use of MAR1-5A3 in vivo, we chose three
in vivo mouse models known to be dependent on type I IFN
that covered a range of functional processes. First, antibody
blockade of IFNAR-1 in wild-type mice produced the same increased sensitivity to viral infection as deletion of the Ifnar1
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gene.15,47 Second, mAb blockade of IFNAR-1 in normal mice
led to the same protective effects against Listeria infection as
was noted in Ifnar1/ mice.17,18,48 Third, MAR1-5A3 treatment of wild-type mice not only produced the same effects as
Ifnar1 gene deletion in ablating host-protective immune responses against tumors20 but also provided the added benefit
of establishing at least some of the temporal requirements for
type I IFN action during the process. Thus, the mAb allowed
us, for the first time, to assess the effects of type I IFN depletion at different stages of disease pathogenesis and thus obtain
insights that could not have been achieved using gene-targeted
mice. The fact that MAR1-5A3 does not deplete IFNAR-1-bearing host cells in vivo adds significant support to the conclusion
that MAR1-5A3 blockade in mice recapitulates many of the
deficits observed in gene-targeted animals.
Having thus produced and characterized the first functionblocking mAbs to murine IFNAR-1, we used them to address
the still unanswered question of whether, in murine cells, cell
surface expression of IFNAR-1 depends on the presence of the
Tyk2 Janus kinase. It is well established that Tyk2 constitutively associates with the intracellular domains of human and
murine IFNAR-1 and is required to maintain expression of human IFNAR-1 at the cell surface.60,61 Mutated U1A human tumor cells that lack Tyk2 are unresponsive to IFN- because they
fail to sustain cell surface expression of IFNAR-1.50,51,62 Subsequent work revealed that the association of Tyk2 with the
IFNAR-1 intracellular domain modifies the trafficking and rate
of internalization of IFNAR-1,49 yet cells from mice with a targeted disruption of the Tyk2 gene are still able to manifest substantial amounts of type I IFN-dependent antiviral activity,45,63,64 suggesting that significant differences exist between
the roles of Tyk2 in mouse vs. human type I IFN receptors. Using the MAR1 mAbs produced in this study, we found comparable expression of IFNAR-1 on the surface of cells from mice
that either express or lack Tyk2. Thus, this observation reveals
that Tyk2’s chaperone functions differ between humans and
mice and, although critical for maintaining expression of human IFNAR-1 at the cell surface, are not needed to maintain
expression of the mouse protein. Additional studies will be
needed to dissect the mechanisms by which murine cells respond to type I IFNs in the absence of Tyk2.
Thus, in sum, we have documented a method involving in vivo
genetic hydrodynamic transfection/immunization of Ifnar1-deficient mice to develop murine IFNAR-1-specific mAbs capable of
interacting with the native murine receptor protein at the cell surface. These mAbs inhibit type I IFN responses in vitro, and one
has been shown to effectively block type I IFN responses in vivo.
The availability of these monoclonal murine IFNAR-1-specific
reagents should facilitate investigations into the biosynthesis and
trafficking of IFNAR-1, help to elucidate the interactions between
different type I IFN subtypes with the IFN-/ receptor, and assist in identifying the physiologic roles of type I IFN in normal
and disease states in vivo to complement questions that cannot be
answered ty the use of Ifnar1-deficient mice.
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